|本期目录/Table of Contents|

[1]陈凤,唐怡敏,黎倩卉,等.抗结核药物肝损伤ALDH2基因多态性分析[J].中华肺部疾病杂志,2022,(01):103-105.[doi:10.3877/cma.j.issn.1674-6902.2022.01.030]
点击复制

抗结核药物肝损伤ALDH2基因多态性分析(PDF)

《中华肺部疾病杂志》[ISSN:1006-6977/CN:61-1281/TN]

卷:
期数:
2022年01期
页码:
103-105
栏目:
短篇论著
出版日期:
2022-02-20

文章信息/Info

Title:
-
作者:
陈凤1; 2; 唐怡敏2; 黎倩卉1; 刘映霞2; 王菲1
518107 深圳,中山大学附属第七医院消化医学中心1 518112 深圳,深圳市第三人民医院感染科2
Author(s):
-
关键词:
抗结核药;  药物性肝损伤;  ALDH2;  多态性
Keywords:
-
分类号:
R521.9
DOI:
10.3877/cma.j.issn.1674-6902.2022.01.030
摘要:
-
Abstract:
-

参考文献/References:

1 Zhang Q, Wu Z, Zhang Z, et al. Efficacy and effect of free treatment on multidrug-resistant tuberculosis[J]. Exp Ther Med, 2016, 11(3): 777-782.
2 任成山, 林 辉, 杨仕明. 结核病的流行特征与耐多药的窘迫及其策略[J/CD]. 中华肺部疾病杂志(电子版), 2019, 12(3): 269-274.
3 杨 松, 郭建琼, 严晓峰. 抗结核药物性肝损伤发生机制的研究进展[J]. 中华结核和呼吸杂志, 2019, 42(5): 378-381.
4 Germani G, Battistella S, Ulinici D, et al. Drug induced liver injury: from pathogenesis to liver transplantation[J]. Minerva Gastroenterol(Torino), 2021, 67(1): 50-64.
5 Xu H, Zhang Y, Ren J. ALDH2 and stroke: asystematic review of the evidence[J]. Adv Exp Med Biol, 2019, 1193: 195-210.
6 Zheng Y, Ning C, Zhang X, et al. Association between ALDH-2 rs671 and essential hypertension risk or blood pressure levels: asystematic review and meta-analysis[J]. Front Genet, 2020, 11: 685.
7 Chen J, Huang W, Cheng CH, et al. Association between aldehyde dehydrogenase-2 polymorphisms and risk of alzheimer'sdisease and parkinson'sdisease: ameta-analysis based on 5,315 individuals[J]. Front Neurol, 2019, 10: 290.
8 中华医学会结核病学分会. 《肺结核诊断和治疗指南(2001年订)》[J]. 内科危急重症杂志, 2002, 8(4): 225-229.
9 于乐成, 茅益民, 陈成伟.《药物性肝损伤诊治指南》[J]. 实用肝脏病杂志, 2017, 20(2): 257-274.
10 沈 弢, 黄 昕, 王誉雅, 等. 我国药物性肝损伤流行病学研究现状[J]. 临床肝胆病杂志, 2018, 34(6): 1152-1155.
11 Xu N, Yang JX, Yang J. Incidence and associated risk factors of antituberculosis drug-induced hepatotoxicity among hospitalised patients in Wuhan, China[J]. Eur J Hosp Pharm, 2020, ejhpharm-2020-002433.
12 Seo W, Gao Y, He Y, et al. ALDH2 deficiency promotes alcohol-associated liver cancer by activating oncogenic pathways via oxidized DNA-enriched extracellular vesicles[J]. J Hepatol, 2019, 71(5): 1000-1011.
13 Zhang R, Wang J, Xue M, et al. ALDH2-The genetic polymorphism and enzymatic activity regulation: their epidemiologic and clinical implications[J]. Curr Drug Targets, 2017, 18(15): 1810-1816.
14 Wang LS, Wu ZX. ALDH2 and cancer therapy[J]. Adv Exp Med Biol, 2019, 1193: 221-228.
15 Ushijima K, Ogami C, Tsuji Y, et al. Presence of the aldehyde dehydrogenase 2 variant ALDH2*2 considerably increases EC50 of nitroglycerin[J]. Eur J Clin Pharmacol, 2021, 77(3): 431-433.

备注/Memo

备注/Memo:
基金项目: 国家自然科学基金资助项目(81800525,81873573)
通信作者: 王 菲, Email: fay_wong1116@hotmail.com
更新日期/Last Update: 2022-02-20